Investors & Media
News
March 27, 2014
SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus
SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus
SAGE Therapeutics Initiates Phase 1/2 Trial of SAGE-547 in Status Epilepticus